Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges for drug studies in children: CYP3A phenotyping as example.

Drug discovery today - 1 Jan 2009

de Wildt Saskia N, Ito Shinya, Koren Gideon

Abstract excerpt

A paucity of data exists on the disposition and effect of drugs in young children. This information gap can be reduced by elucidating developmental principles of absorption, distribution, metabolism and excretion (ADME) in vivo. Such knowledge might enable the prediction of the disposition of individual drugs in children over the whole pediatric age range. CYP3A, the most abundant human drug metabolizing enzyme,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Child
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Pharmaceutical Preparations

Share to Pharmacokinetics

Share to Phenotype

Source

Identifiers

PMID: 18721895
DOI: 10.1016/j.drudis.2008.07.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges for drug studies in children: CYP3A phenotyping as example.PMID 18721895Read ↗

Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children.Semantic proximity Read ↗

Phenotyping of drug metabolism in infants and children: potentials and problems.Semantic proximity Read ↗

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.Semantic proximity Read ↗

Identifying genomic and developmental causes of adverse drug reactions in children.Semantic proximity Read ↗

Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children.Semantic proximity Read ↗

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.Semantic proximity Read ↗

Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modelingSemantic proximity Read ↗

The role of cytochrome P450 in developmental pharmacology.Semantic proximity Read ↗

Pharmacokinetics in the child.Semantic proximity Read ↗

In vitro ADME phenotyping in drug discovery: current challenges and future solutions.Semantic proximity Read ↗

Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolismSemantic proximity Read ↗

In vitro cytochrome p450 activity decreases in children with high pediatric end-stage liver disease scores.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.